The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
These stories were later popularized by Harvard-trained ethnobotanist Wade Davis in his 1985 book and Wes Craven's 1988 film, both titled The Serpent and the Rainbow. James Ellroy includes "blowfish toxin" as an ingredient in Haitian Vodou preparations to produce zombieism and poisoning deaths in his 2009 novel Blood's a Rover. However, this theory has been questioned by the scientific community since the 1990s based on analytical chemistry-based tests of multiple preparations and review of earlier reports (see above).
=== 10 June === The SAF accused the LNA of carrying out a joint attack with the RSF in the Libya-Egypt-Sudan border triangle. Eight people were killed in an SAF drone attack on a school sheltering IDPs in Abu Zabad, West Kordofan.
=== TIME acronym (Tissue, Inflammation and Infection, Moisture, Epithelial) === Since the year 2000, the wound bed preparation concept has continued to improve. For example, the TIME acronym (Tissue management, Inflammation and infection control, Moisture balance, Epithelial (edge) advancement) has supported the transition of basic science to the bedside in order to exploit appropriate wound healing interventions and has not deviated from the important tenets of debridement, moisture balance, and bacterial balance. The TIME framework is not a continuum and as such is applicable to a wide range of wounds. The WBP model can be effectively applied only when a high level of precision is utilized in the assessment of the patient and their wound. The corollary of this is that intervention demands an equally high level of precision and this should be preceded by a comprehensive wound assessment.
Sources: en.wikipedia.org
The study of well-being originated in antiquity, often in the form of discussions on how to lead a good life. Socrates (c. 470 – c. 399 BCE) rejected power, fame, wealth, and the hedonistic pursuit of pleasure as paths to lasting happiness, arguing instead that wisdom and virtue are key elements of well-being. He held that lifelong learning and philosophical reflection cultivate an examined life, promote moral excellence, and align with the good. Influenced by Socrates, Aristotle (384–322 BCE) developed a eudaimonic theory of well-being. He maintained that well-being is the purpose of life and is achieved primarily by practicing virtues, such as acting in accordance with reason, justice, courage, and temperance. Aristotle distinguished three general factors that contribute to well-being: goods of the soul, such as intellectual and moral virtues; goods of the body, such as health; and external goods, such as wealth and good relations to others. In Hellenistic philosophy, starting in the 4th century BCE, the Epicureans and the Stoics considered well-being an internal state independent of external conditions. The Epicureans argued that pleasure is the only source of well-being and that it is best achieved through moderation and the cultivation of a tranquil state of mind. The Stoics emphasized discipline and rational virtue as the key to well-being.
Larry Friedman (Mulligan) performed in the musical Rasputin with Ted Neeley and John Hurt. Mion Hahm (Micki) is a realtor in Florida. Steve Einbender (Mike) is Senior Manager of Customer Analytics for The Home Depot, in Atlanta, Georgia. He still plays drums. Benjamin Sands (Manny) is a music teacher in the Washington, D.C. area. Sherry Wright (Maggie) pursued an acting and singing career while living in Alexandria, Virginia; she died in July 2009. Barry Michlin (Wilbur) had a number of minor roles throughout the 1970s and 1980s, and also made recurring appearances in several TV commercials including for Arm & Hammer Baking Soda with actress Beverly Sanders. He is a photographer based in Los Angeles.
The track is the first in a trilogy, with the second track, "Too Old for the Dumb Shit", described as a prequel to "Feds in My Rearview", and released in September 2019. Ice-T was also featured on the 2020 hip-hop posse cut "The Slayers Club" alongside R.A. the Rugged Man, Brand Nubian and others. Ice-T performed at New Year's Eve Toast & Roast 2021, Fox broadcast.
Sources: en.wikipedia.org
1 L-ornithine2 carbamoyl phosphate3 L-citrulline4 argininosuccinate5 fumarate6 L-arginine7 urea L-Asp L-aspartateCPS-1 carbamoyl phosphate synthetase IOTC Ornithine transcarbamoylaseASS argininosuccinate synthetaseASL argininosuccinate lyaseARG1 arginase 1
==== 300–399 ==== Goods Vehicles (Operators' Licences, Qualifications and Fees) (Amendment) Regulations 1993 (S.I. 1993/301) Mines (Shafts and Winding) Regulations 1993 (S.I. 1993/302) Housing (Right to Buy) (Priority of Charges) Order 1993 (S.I. 1993/303) Mortgage Indemnities (Recognised Bodies) Order 1993 (S.I. 1993/304) Folkestone-Brighton-Southampton-Dorchester-Honiton Trunk Road (Guestling Thorn Diversion) (Revocation) Order 1993 (S.I. 1993/305) Local Authorities (Capital Finance) (Rate of Discount for 1993/94) Regulations 1993 (S.I. 1993/312) Police (Amendment) Regulations 1993 (S.I. 1993/313) Gipsy Encampments (City and District of St. Albans) Order 1993 (S.I. 1993/314) Income-related Benefits Schemes (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/315) Social Security (Invalid Care Allowance) Amendment Regulations 1993 (S.I. 1993/316) Housing Benefit (General) Amendment Regulations 1993 (S.I. 1993/317) Humberside Ambulance Service National Health Service Trust (Establishment) Amendment Order 1993 TI> S.I. 1993/318) Maidstone Priority Care National Health Service Trust (Establishment) Amendment Order 1993 (S.I. 1993/319) Royal Bournemouth and Christchurch Hospitals National Health Service Trust (Transfer of Trust Property) Order 1993 (S.I. 1993/320) Caledonian MacBrayne Limited (Armadale) Harbour Revision Order 1992 S.I. 1993/321) Revenue Support Grant (Scotland) Order 1993 (S.I. 1993/322) Town and Country Planning (Hazardous Substances) (Scotland) Regulations 1993 (S.I. 1993/323) A23 Trunk Road (Streatham High Road, Lambeth) (Box Junction) Order 1993 (S.I.
The exact dose of lithium given varies depending on factors such as the patient's serum lithium concentrations, which must be closely monitored by a physician to avoid lithium toxicity and potential kidney damage (or even kidney failure) from lithium-induced nephrogenic diabetes insipidus. Dehydration and certain drugs, including NSAIDs such as ibuprofen, can increase serum lithium concentrations to unsafe levels whereas other drugs, such as caffeine, may decrease concentrations.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.